A Trial Comparing Efficacy of HM3 Versus F2 Lithotripters for Stone Fragmentation

Stopped early · Not applicable

Conditions studied: Urolithiasis

In brief

The older lithotripter, HM3, has over 90% stone-free rate in most studies. However, it's less transportable than the new model, F2. There are no prospective trials performed to make a valid comparison between these 2 lithotripters in terms of efficacy of stone fragmentation and clinical outcomes.

Key facts

Study ID

NCT00913159

Run by

Washington University School of Medicine

People needed

5

Starts

2009-11-01

Expected to finish

2010-08-01

Last updated by the study team

2010-10-18

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with urolithiasis and choose to have ESWL treatment
• Age 18-90 years old
• Able to understand the informed consent

You may not qualify if…

• Minors
• Cognitively impaired

Where it is running

• Division of Urology, Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.